Blog tagged as ICH E6(R3)

As the market share leader across NCI Comprehensive Cancer Centers, Yunu has transformed imaging at scale through rapid adoption. What began as a trusted site solution is now a strategic platform for sponsors, bringing greater rigor, confidence, and consistency to central review workflows.

Site-level imaging errors affect up to 50% of oncology trial reads, delaying trials and potentially censoring patients. When quality is enforced at the point of capture, error rates drop by more than 80%, saving millions of dollars and months in trial timelines.

Moe Alsumidaie’s latest article explores how the updated ICH E6(R3) guidance raises the bar for imaging in clinical trials. With imaging as the primary endpoint in most oncology studies, sites and sponsors must now meet the same Good Clinical Practice (GCP) standards as other critical data types.